7-(morpholinyl)-2-(n-piperazinyl) methyl thieno [2, 3-c] pyridine derivatives as anticancer drugs

A pharmaceutical composition comprising:

• (a) a therapeutically effective amount of a 7-(Morpholinyl)-2-(N-piperazinyl)methyl Thienor[2, 3-c]pyridine compound of Formula-I or a pharmaceutically acceptable salt thereof,
• wherein:
• R1 is H. C1-C6 alkyl, C3-C6 cycloalkyl, —C(O)R5, —S(O)2R5, —C(O)2R5 C1-C6 alkyl substituted with R6, C3-C6 cycloalkyl substituted with R6, aryl, aryl substituted with R6 or heteroaryl substituted with R6;
• R2, R3 and R4 are each independently H, —OH, —SH, halo, amino, cyano, -nitro, C1-C6 alkyl, C3-C6 cycloalkyl, aryl, lower alkoxy group, —C(O)R5, —S(O)2R5, —C(O)2R5, —C═C(H)—R6, aminocarbonyl substituted with R6, alkylamino group substituted with R6 and optionally containing C3-C6 cycloalkyl, -alkylaminocarbonyl, arylaminocarbonyl, heteroaryl, heteroaryl optionally substituted with H, amino, aminoalkyl or aminocycloalkyl containing C3-C6 carbon atoms, fused bicyclic or tricyclic heteroaryl containing 1, 2 or 3 heteroatoms such as N, O or S, or aryl optionally substituted with hydroxyl, hydroxylalkyl, amino, aminoalkyl, aminocarbonyl, alkynyl, cyano, halogen, lower alkoxy, aryloxy or R6;
• R5 is H, alkyl, amino, aminoalkyl, -N(alk)2, aryl substituted with R6, heteroaryl substituted with R6, fused heteroaryl substituted with R6 or -trifluoromethyl;
• R6 is H, hydroxy, halogen, cyano, nitro, amino, C1-C6 alkyl, -N(alk)2, substituted alkyl (CH)0-6, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted aralkyloxy, aryl(hydroxyl)alkyl, aromatic acylamino, arylsulfonylamino, lower alkoxyl aryl sulfonylamino, hydroxyl lower alkoxyl styryl, lower alkoxyl aryloxy, optionally substituted arylalkenyl, heteroarylalkenyl, heteroarylalkynyl, aromatic acyl alkynyl, optionally N-substituted amino lower alkyl, arylamino or arylalkylamino;
• and
• (b) a pharmaceutically acceptable carrier, diluent or vehicle.

A method for treating cancer, said method comprising:

• administering to a human a therapeutically effective amount of a 7-(Morpholinyl)-2-(N-piperazinyl)methyl thieno[2, 3-c]pyridine compound of Formula-I or a pharmaceutically acceptable salt thereof,
• wherein:
• R1 is H, C1-C6 alkyl, C3-C6 cycloalkyl, —C(O)R5, —S(O)2R5, —C(O)2R5,
• C1-C6 alkyl substituted with R6, C3-C6 cycloalkyl substituted with R6, aryl, aryl substituted with R6 or heteroaryl substituted with R6;
• R2, R3 and R4 are each independently H, —OH, —SH, halo, amino, cyano, -nitro, C1-C6 alkyl, C3-C6 cycloalkyl, aryl, lower alkoxy group, —C(O)R5, —S(O)2R5, —C(O)2R5, —C═C(H)—R6, aminocarbonyl substituted with R6, alkylamino group substituted with R6 and optionally containing C3-C6 cycloalkyl, -alkylaminocarbonyl, arylaminocarbonyl, heteroaryl, heteroaryl optionally substituted with H, amino, aminoalkyl or aminocycloalkyl containing C3-C6 carbon atoms, fused bicyclic or tricyclic heteroaryl containing 1, 2 or 3 heteroatoms such as N, O or S, or aryl optionally substituted with hydroxyl, hydroxylalkyl, amino, aminoalkyl, aminocarbonyl, alkynyl, cyano, halogen, lower alkoxy, aryloxy or R6;
• R5 is H, alkyl, amino, aminoalkyl, -N(alk)2, aryl substituted with R6, heteroaryl substituted with R6, fused heteroaryl substituted with R6 or -trifluoromethyl,
• R6 is H, hydroxy, halogen, cyano, nitro, amino, C1-C6 alkyl, -N(alk)2, substituted alkyl (CH)0-6, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted aralkyloxy, aryl(hydroxyl)alkyl, aromatic acylamino, arylsulfonylamino, lower alkoxyl aryl sulfonylamino, hydroxyl lower alkoxyl styryl, lower alkoxyl aryloxy, optionally substituted arylalkenyl, heteroarylalkenyl, heteroarylalkynyl, aromatic acyl alkynyl, optionally N-substituted amino lower alkyl, arylamino or arylalkylamino.